German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
The CSIRO has successfully appealed a decision that blocked the government agency’s application to patent a method of producing high-fibre wheat.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.
Andrew ‘Twiggy’ Forrest’s Fortescue can’t get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.
J&J-owned Janssen Pharmaceutica has sued Juno Pharmaceuticals, alleging the Australian off-patent drug maker is threatening to infringe its patent for a schizophrenia drug by seeking to list its own products on the PBS.
Nike has lost its challenge to a Canberra AFL club’s trade mark, with IP Australia finding that the “arc-like feature” depicting a football in flight was not deceptively similar to the sportswear giant’s iconic swoosh mark.
IP boutique Davies Collison Cave has brought proceedings against its Melbourne landlord at the Orica House, seeking a declaration that it has not abandoned its lease.
Puma has appealed its failed opposition to a trade mark for Tiger Woods’ golf apparel and equipment brand Sun Day Red, which the German sneaker giant argued was too similar to its iconic leaping cat mark.